Shanghai Exuma Biotechnology Ltd.
EXUMA Biotech is a clinical-stage biotechnology company dedicated to developing gene vector delivery solutions and products to improve patient access to innovation in cell and gene therapy. They focus on platform technologies that enhance the efficacy, safety, and durability of CAR-T products without requiring chemotherapy, aiming to make cell therapy more accessible and safer for broader patient populations.
Industries
Nr. of Employees
medium (51-250)
Shanghai Exuma Biotechnology Ltd.
Grand Cayman, Midland, Cayman Islands, North America
Products
Subcutaneous autologous CAR-T production platform
A platform workflow that incubates PBMCs with a T cell–targeted viral vector and administers the formulation subcutaneously to generate a local synthetic lymph node that matures and expands CAR-T cells in vivo without preparative lymphodepletion.
In vivo CAR engineering platform
Platform for direct in vivo CAR induction using formulated T cell–targeted vectors and signaling transgenes to create and expand CAR-T cells within existing lymph nodes.
T cell–targeted viral vector preparations
Engineered viral vector products formulated for ex vivo or in vivo transduction of CD3+ lymphocytes to enable CAR expression and subsequent expansion.
Semi-synthetic signaling transgene constructs
Compact, multi-unit signaling constructs identified by high-throughput screening to optimize effector cell stemness, proliferation, persistence, and cytotoxicity for chemotherapy-free in vivo expansion.
Tumor metabolism–regulated CAR constructs
CARs designed to exploit metabolic differences in the tumor microenvironment to achieve reversible, selective binding and improve safety when targeting antigens also present on normal tissues.
mRNA-encoded synthetic CAR ligands
Off-the-shelf mRNA constructs encoding non-CAR target epitopes that can be administered to modulate CAR pharmacokinetics and provide antigen-independent stimulation to control CAR-T persistence and expansion.
Subcutaneous autologous CAR-T production platform
A platform workflow that incubates PBMCs with a T cell–targeted viral vector and administers the formulation subcutaneously to generate a local synthetic lymph node that matures and expands CAR-T cells in vivo without preparative lymphodepletion.
In vivo CAR engineering platform
Platform for direct in vivo CAR induction using formulated T cell–targeted vectors and signaling transgenes to create and expand CAR-T cells within existing lymph nodes.
T cell–targeted viral vector preparations
Engineered viral vector products formulated for ex vivo or in vivo transduction of CD3+ lymphocytes to enable CAR expression and subsequent expansion.
Semi-synthetic signaling transgene constructs
Compact, multi-unit signaling constructs identified by high-throughput screening to optimize effector cell stemness, proliferation, persistence, and cytotoxicity for chemotherapy-free in vivo expansion.
Tumor metabolism–regulated CAR constructs
CARs designed to exploit metabolic differences in the tumor microenvironment to achieve reversible, selective binding and improve safety when targeting antigens also present on normal tissues.
mRNA-encoded synthetic CAR ligands
Off-the-shelf mRNA constructs encoding non-CAR target epitopes that can be administered to modulate CAR pharmacokinetics and provide antigen-independent stimulation to control CAR-T persistence and expansion.
Services
Platform development and clinical translation for cell and gene therapies
Research and development services to advance autologous and in vivo cell therapies from preclinical discovery through early clinical evaluation, including vector engineering, transgene optimization, and translational studies.
Platform development and clinical translation for cell and gene therapies
Research and development services to advance autologous and in vivo cell therapies from preclinical discovery through early clinical evaluation, including vector engineering, transgene optimization, and translational studies.
Expertise Areas
- Clinical-stage development and early clinical trials
- Lentiviral vector engineering and formulation
- Autologous cell therapy manufacturing and process shortening
- In vivo CAR-T engineering and delivery
Key Technologies
- Lentiviral vectors
- T cell–targeted lentivectors
- Subcutaneous synthetic lymphoid structure formation via injection
- In vivo CAR induction and expansion